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Abstract
Objectives
To estimate mortality rates and prognostic factors in HIV-positive patients who started com-
bination antiretroviral therapy between 1996–1999 and survived for more than ten years.
Methods
We used data from 18 European and North American HIV cohort studies contributing to the
Antiretroviral Therapy Cohort Collaboration. We followed up patients from ten years after
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start of combination antiretroviral therapy. We estimated overall and cause-specific mortal-
ity rate ratios for age, sex, transmission through injection drug use, AIDS, CD4 count and
HIV-1 RNA.
Results
During 50,593 person years 656/13,011 (5%) patients died. Older age, male sex, injecting
drug use transmission, AIDS, and low CD4 count and detectable viral replication ten years
after starting combination antiretroviral therapy were associated with higher subsequent
mortality. CD4 count at ART start did not predict mortality in models adjusted for patient
characteristics ten years after start of antiretroviral therapy. The most frequent causes of
death (among 340 classified) were non-AIDS cancer, AIDS, cardiovascular, and liver-
related disease. Older age was strongly associated with cardiovascular mortality, injecting
drug use transmission with non-AIDS infection and liver-related mortality, and low CD4 and
detectable viral replication ten years after starting antiretroviral therapy with AIDS mortality.
Five-year mortality risk was <5% in 60% of all patients, and in 30% of those aged over 60
years.
Conclusions
Viral replication, lower CD4 count, prior AIDS, and transmission via injecting drug use con-
tinue to predict higher all-cause and AIDS-related mortality in patients treated with combina-
tion antiretroviral therapy for over a decade. Deaths from AIDS and non-AIDS infection are
less frequent than deaths from other non-AIDS causes.
Introduction
HIV-positive patients who started combination antiretroviral therapy (ART) soon after it
became widely available in Europe and North America in 1996 have been treated for up to 20
years[1]. Current mortality rates in these patients are of great interest: they started ART regi-
mens that are less tolerable and have lower antiviral potency than those now available[2] and
are likely to have switched ART regimen repeatedly as better drugs became available[3, 4]. As
they age these patients are at increased risk of age-related comorbidities such as cardiovascular
disease, cancer, liver and renal disease[5, 6]. The proportion of deaths classified as AIDS has
decreased over this period[7, 8]. Prognosis beyond the first decade of ART is thus of interest to
patients, their treating physicians, mathematical modellers, and those planning health
resources.
In the early ART era, mortality was high in the first year of ART and decreased thereafter[9,
10]. For patients who started treatment with immune suppression, AIDS-related causes of
death dominate soon after starting ART, but later decline relative to non-AIDS causes[5, 11,
12]. For some successfully treated patient groups mortality rates may be similar to those of the
background population[13, 14].
Several factors predict short-term mortality in HIV positive patients starting ART[9, 10],
but the prognostic value of some of these factors (for example CD4 count at ART start) dimin-
ishes with time[15]. We studied factors that are prognostic for mortality in a large patient
cohort who started combination ART without previous exposure to antiretroviral drugs and
were treated for a decade. We determined all-cause and cause-specific mortality rates and
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identified clinical and demographic risk factors for all-cause and cause-specific mortality pres-
ent ten years after starting ART.
Methods
The Antiretroviral Therapy Cohort Collaboration (ART-CC) combined data from HIV cohorts
in North America and Europe on HIV-1 positive patients aged at least 16 years who started
ART with at least three drugs[16] without prior exposure to antiretroviral medications. Further
details on the dataset can be found elsewhere (www.art-cohort-collaboration.org). Cohorts
were approved by ethics committees or institutional review boards, used standardized methods
of data collection, and scheduled follow-up visits at least every six months. Data were analysed
anonymously. Eligible patients started ART during 1996–9, remained alive and in follow-up
for at least ten years after ART start, and had at least one CD4 count and viral load measure-
ment between nine and ten years after ART start. We used the CD4 count measured before
and closest to ART start date plus 10 years. Patients who had stopped or interrupted ART were
included. Data analysed were compiled from 18 cohorts (Appendix 1) with follow up until 31st
July 2013.
Information relevant to assigning causes of death was obtained either through linkage with
Vital Statistics agencies and hospitals or through physician report and active follow-up. We
adapted the Cause of Death (CoDe) project protocol[17] (www.cphiv.dk/CoDe.aspx) to classify
causes of death. If ICD-10 codes were available, causes of death were classified by a clinician
and a computer algorithm[18]. When ICD-10 codes were not available, two clinicians indepen-
dently classified each death. Disagreements between clinicians and/or computer-assigned
codes were resolved via panel discussion[5]. Deaths were coded as AIDS-related if there was a
serious AIDS defining condition prior to death and/or a low CD4 count (<100/μL) within a
year (18 months if off treatment) of death, and a diagnosis compatible with AIDS as cause of
death[6]. All other deaths, including those of unknown cause, were considered non-AIDS
related. Cause of death information was analysed for six cohorts for which causes had been
classified for over 70% of deaths.
Statistical Methods
Follow-up started ten years after ART start and ended at the earliest of death, loss to follow-up
(LTFU) or administrative censoring (cohort-specific database close date). Patients were consid-
ered LTFU at their last clinical observation if this was over a year before the close date. AIDS
was categorised as: no recorded AIDS diagnosis; first AIDS diagnosis before starting ART; and
first AIDS diagnosis between starting ART and start of follow-up. Drug regimens were derived
at ART start and start of follow-up and were classified as NNRTI-based, PI-based, other regi-
men, or no drugs at start of follow-up.
We compared characteristics of eligible patients with those no longer followed-up at ten
years after start of ART because they died, were LTFU or transferred to another treatment cen-
tre. We estimated unadjusted mortality rates assuming constant rates during follow-up. Five-
year cumulative mortality was estimated using the Kaplan-Meier method. We used Cox models
to estimate unadjusted and adjusted hazard ratios (HR): adjustments were for sex, regimen, age
(16–39, 40–49, 50–59, 60–69,70 years), mode of transmission (injection drug use [IDU] or
not), and HIV-1 RNA (0–50, 51–1000,1001copies/mL), CD4 count (0–99, 100–199, 200–
349, 350–499, 500–749,750 cells/μL) and AIDS status at start of follow-up, chosen due to
prior literature[19]. We investigated whether CD4 count at ART start was associated with mor-
tality after accounting for the association of CD4 count 10 years after ART start.
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We tabulated frequencies of AIDS, non-AIDS, and specific causes of death. We estimated
adjusted HR for the more frequent (n10) specific causes of death (AIDS, cardiovascular,
liver-related, malignancies (non-AIDS and not hepatitis-related), suicide/accidents) stratified
by age (60 vs.<60 years), sex, IDU status, CD4 count (<200 vs.200 cells/μL), viral sup-
pression (HIV-1 RNA>50 vs.50 copies/mL), and AIDS diagnosis during or before the first
decade of ART (vs. no AIDS). Five-year cumulative risks of death, according to age, risk group
and CD4 count, viral load and AIDS status recorded ten years after starting ART, were esti-
mated using cumulative incidence functions from a flexible Weibull model[20], stratified by
IDU and CD4 count. We estimated five-year mortality risk for each patient and tabulated the
frequency distribution of patients grouped by five-year mortality risk (0–1.99, 2–4.99, 5–9.99,
10–24.99 and25%) by age (<60 and60 years). We compared five-year mortality risk in
HIV-positive individuals with that of age-matched French general population in 2013 using
mortality.org data. We chose the French population as comparator because the largest propor-
tion of patients were treated in France. As a sensitivity analysis we used competing risks regres-
sion with LTFU and death as the competing outcomes[21]. Analyses were done using Stata 13
(StataCorp, Texas, USA).
Results
24,445 patients started ART between 1996–1999. Of these, 3,577 (15%) died, 5,963 (24%) were
LTFU during the first decade of ART, and 1,894 (8%) were excluded because CD4 count or
viral load were not available at start of follow-up leaving 13,011 (53%) patients eligible for anal-
yses. Table 1 compares characteristics at ART start of eligible patients with excluded patients
who died, were LTFU, or lacked a measurement of CD4 and viral load between nine and ten
years after ART start. The two groups had similar age distributions, but eligible patients were
less likely to be IDU (1,636 [13%] vs 2,623 [23%]), had higher CD4 count and lower viral load
at ART start.
Among 13,011 patients during follow-up from 10 years after starting ART, there were 656
deaths during 50,593 person years giving a crude mortality rate of 12.9 [95% CI 12.0,14.0] per
1,000 person years, and estimated five year survival 93.5% (93.1–94.2%). Median (IQR) follow-
up was 4.0 (3.1–5.0) years and maximum follow-up time varied between cohorts from 4.5 to
7.1 years. The rate of LTFU was 5.5 (95% CI 5.3–5.7) per 100 person years (N = 5,963). Patients
LTFU after 10 years were more likely to be female, IDU and younger (Table 2). Median (IQR)
CD4 count at ten years after starting ART was lower in those who died, but was similar in
those LTFU or who remained in care: 383 (185–554), 535 (350–740), and 566 (390–774) cells/
μL, respectively. The proportions of patients with HIV-RNA50 copies/mL at ten years after
starting ART was lower in those who died, but similar in those LTFU or who remained in care:
56%, 73%, and 77%, respectively (Table 2).
Patient demographics and clinical characteristics at start of follow-up (ten years after start-
ing ART) are shown in Table 3. Median (IQR) CD4 count was 250 (100–401) cells/μL at ART
start and increased to 550 (371–760) cells/μL at ten years. The correlation between CD4 count
at ART start and at ten years was 0.27 (p<0.001). Most patients (11,504; 88%) had HIV-1 RNA
200 copies/mL ten years after ART start. At ART start most patients (10,266; 79%) were on
PI-based regimens with 2,229 (17%) on NNRTI-based regimens. By ten years 4,555 (35%) and
5,002 (39%) of patients were on PI- and NNRTI-based regimens, respectively, whilst 1,072
(8%) were off ART. Of the remaining patients, 1,853 (14%) were only receiving NRTIs, 108
(1%) and 9 (0.1%) were on CCR5 receptor antagonist- and integrase inhibitor-based regimens
respectively and 3% were on other regimens. Of 400 (3%) patients with CD4 count<100 cells/
μL ten years after ART start, 71 (18%) were not on treatment, 1,001 (8%) of those with CD4
Mortality after 10 Years of ART
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count100 cells/μL ten years after ART start were not on treatment. The proportions of virally
suppressed patients (HIV-1 RNA<50 copies/mL) were 30% and 77% for those with CD4
counts<100 and100 cells/μL, respectively. There were 6,287 (48%) patients with HIV-1
RNA<50 copies/mL and with CD4 count500 cells/μL.
Mortality from ten years after start of ART
Mortality was substantially higher in patients aged 60–69 and>70 years from ten years after
starting ART (adjusted HR 4.29 [95% CI 3.06–6.02] and 8.59 [5.82–12.7] respectively com-
pared with age 16–39 (Table 3)). Mortality was also substantially higher in patients with CD4
count<100 cells/μL from ten years after ART start (adjusted HR 6.17 [4.46–8.53] compared
with750 cells/μL). Mortality rates were similar in patients with CD4 count 500–749 and
750 cells/μL. Mortality was higher in IDU compared with non-IDU (adjusted HR 2.58 [2.04–
3.26]). Viral load>1000 copies/mL at ten years and an AIDS diagnosis in the first ten years
Table 1. Characteristics (at start of ART) of patients who were and were not eligible for analyses of prognosis from 10 years after start of ART.
Patients who started ART 1996–1999 but were
excluded from analyses
Patients included in analyses of prognosis from 10 years after start of
ART
Characteristics Number (%) of patients Number (%) of deaths Numbers (%) of patients
Total 11,434 (100%) 13,011 (100%)
IDU 2,623 (23%) 820 (31%) 1,636 (13%)
Female 2,215 (19%) 472 (21%) 2,701 (21%)
AIDS diagnosis 2,613 (23%) 1,250 (48%) 2,714 (21%)
Age (years)
Median (IQR) 36 (31, 43) 36 (31,43)
16–29 2,127 (19%) 330 (16%) 2,330 (18%)
30–39 5,147 (45%) 1,335 (26%) 6,029 (46%)
40–49 2,600 (23%) 1,148 (44%) 3,129 (24%)
50–59 1,089 (10%) 614 (56%) 1,181 (9%)
60 471 (4%) 296 (63%) 342 (3%)
CD4 count (cell/μL)
Median (IQR) 224 (85, 335) 250 (100, 401)
750 381 (3%) 70 (19%) 423 (3%)
500–749 1,166 (10%) 251 (22%) 1,483 (11%)
350–499 1,868 (16%) 408 (22%) 2,390 (18%)
200–349 2,799 (24%) 776 (28%) 3,372 (26%)
100–199 2,092 (18%) 775 (37%) 2,120 (16%)
50–99 1,103 (10%) 469 (43%) 1,229 (9%)
25–49 760 (7%) 340 (45%) 748 (6%)
0–24 1,265 (11%) 634 (50%) 1,246 (10%)
HIV 1 RNA cell
count
Median (IQR) 7.4×104 (1.7×104,
2.4×105)
7.1×104 (1.7×104, 2.3×105)
0–50 104 (1%) 11 (11%) 88 (1%)
51–1000 580 (5%) 106 (18%) 669 (5%)
1001–100000 5,766 (50%) 1,645 (29%) 6,794 (52%)
>100000 4,984 (44%) 1,961 (39%) 5,460 (42%)
LTFU: lost to follow-up; IDU: injection drug use; IQR: inter-quartile range
doi:10.1371/journal.pone.0160460.t001
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after starting ART were associated with higher subsequent mortality (adjusted HR 1.74 [1.40–
2.15] and 1.68 [1.37–2.06] respectively). There was no difference in subsequent mortality
between the patients on PI- (adjusted HR 1.17 [0.95–1.43] compared with NNRTI-) and
NNRTI-based regimens at 10 years after ART start.
Lower CD4 count at ART start was weakly associated with higher mortality from ten years
(Table 4). This was attenuated by adjustment for CD4 count at ten years after starting ART
and other covariates, with a suggestion of lower subsequent mortality for patients with very
low CD4 count at ART start after adjustment for ten year CD4 count [HR = 0.62 (0.46–0.83)
for CD4<50 vs.350 cells/μL].
Results were similar to those in the main analysis when LTFU was considered a competing
risk to death in the sensitivity analysis.
Five-year mortality risk
Table 5 shows estimated five-year mortality risk from ten years after ART start in groups
defined by combinations of age, IDU risk group, AIDS status, CD4 count and viral suppres-
sion. For patients aged 40–49 years at ten years after starting ART the subsequent five-year
mortality risk ranged from 1.9% (1.5–2.4%) in those who were non-IDU and virally suppressed
with CD4 count>500 cells/μL and no AIDS, to 48% (40–58%) in those who were IDU and not
Table 2. Characteristics of patients followed from 10 years after start of ART who died, were lost to follow up (LTFU) or remained in the study until
end of follow up.
Number (%) of patients
Died (N = 656) LTFU (N = 2,708) Remained in the study (N = 9,647)
IDU 121 (18%) 474 (18%) 1,041 (11%)
Female 81 (12%) 669 (25%) 1,951 (20%)
No AIDS 302 (46%) 1,867 (69%) 6,492 (67%)
AIDS before ART start 175 (27%) 537 (20%) 2,002 (21%)
AIDS between ART start and 10 years afterwards 179 (27%) 304 (11%) 1,153 (12%)
Age (years)
Median (IQR) 52 (45, 60) 45 (40, 51) 46 (41, 53)
16–39 53 (8%) 606 (22%) 1,671 (17%)
40–49 225 (34%) 1,287 (48%) 4,517 (47%)
50–59 200 (30%) 570 (21%) 2,359 (24%)
60 178 (27%) 245 (9%) 1,100 (11%)
CD4 count (cells/μL)
Median (IQR) 383 (185, 554) 535 (350, 740) 566 (390, 774)
0–99 98 (15%) 97 (4%) 205 (2%)
100–199 81 (12%) 176 (7%) 371 (4%)
200–349 131 (20%) 398 (15%) 1,321 (14%)
350–499 128 (20%) 532 (20%) 1,984 (21%)
500–749 126 (19%) 856 (32%) 3,111 (32%)
750 92 (14%) 649 (24%) 2655 (28%)
Viral load (HIV-1 RNA copies/mL)
% with RNA50 56% 73% 77%
0–50 370 (56%) 1,977 (73%) 7,467 (77%)
51–1000 119 (18%) 365 (13%) 1,206 (13%)
>1000 167 (25%) 366 (14%) 974 (10%)
IDU: injection drug use; IQR: inter-quartile range
doi:10.1371/journal.pone.0160460.t002
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virally suppressed with CD4 count<100 cells/μL and AIDS during the first decade of ART. In
comparison, the 5-year mortality risk in the French general population of the same age was 1%.
Fig 1 shows the proportion of patients in five-year mortality risk strata, for younger (aged<60
years) and older (60) patients. Five-year mortality risk was below 25% in 12,649 (97%)
patients, below 10% in 10,715 (82%) patients and below 5% in 7,829 (60%). Mortality risk was
strongly age-related: only 384 (29%) patients aged60 years had five-year mortality risk less
than 10%.
Cause-specific mortality from ten years after starting ART
There were 218 deaths among 7,178 patients in the eight cohorts with70% of cause of death
information coded. It was possible to classify a cause of death in 180 (83%): the others were
coded unknown/missing. The most frequent cause of death was non-AIDS non-liver cancer
(41 deaths [25% of those classified]) followed by AIDS (35 [19%]), cardiovascular (22 [12%])
Table 3. Characteristics of eligible patients 10 years after start of ART, together with unadjusted and adjusted hazard ratios (HR).
Characteristics Number (%) of patients Number (%) of deaths Unadjusted HR Adjusted HR
(95% CI) (95% CI)*
Total 13,011 (100%) 656 (100%)
Risk group
IDU (vs non-IDU) 1,636 (13%) 121 (7%) 2.54 (2.03, 3.18) 2.58 (2.04, 3.26)
Sex
Female (vs male) 2,701 (21%) 81 (3%) 0.76 (0.60, 0.96) 0.95 (0.74, 1.21)
AIDS diagnosis
No AIDS 8,661 (67%) 302 (3%) 1 1
AIDS before ART start 2,714 (21%) 175 (6%) 1.73 (1.43, 2.09) 1.48 (1.23, 1.80)
AIDS between ART start and 10 years afterwards 1,636 (13%) 179 (11%) 2.14 (1.75, 2.62) 1.68 (1.37, 2.06)
Age (years)
Median (IQR) 46 (41, 53)
16–39 2,330 (18%) 53 (2%) 1 1
40–49 6,029 (46%) 225 (4%) 1.50 (1.11, 2.03) 1.40 (1.04, 1.90)
50–59 3,129 (24%) 200 (6%) 2.15 (1.58, 2.92) 2.14 (1.56, 2.92)
60–69 1,181 (9%) 123 (10%) 3.39 (2.44, 4.71) 4.29 (3.06, 6.02)
70 342 (3%) 55 (16%) 6.18 (4.22, 9.04) 8.59 (5.82, 12.7)
CD4 count (cells/μL)
Median (IQR) 550 (372, 760)
750 3,396 (26%) 92 (3%) 1 1
500–749 4,093 (31%) 126 (3%) 1.12 (0.85, 1.46) 1.01 (0.78, 1.33)
350–499 2,644 (20%) 128 (5%) 1.72 (1.32, 2.25) 1.41 (1.07, 1.84)
200–349 1,850 (14%) 131 (7%) 2.37 (1.81, 3.10) 1.80 (1.37, 2.37)
100–199 628 (5%) 81 (13%) 4.28 (3.16, 5.78) 3.07 (2.24, 4.19)
0–99 400 (3%) 98 (25%) 9.25 (6.90, 12.4) 6.17 (4.46, 8.53)
Viral load (HIV-1 RNA copies/mL)
Median (% with RNA50) 50 (75%)
0–50 9,814 (75%) 370 (4%) 1 1
51–1000 1,690 (13%) 119 (7%) 1.25 (1.00, 1.56) 1.09 (0.87, 1.36)
>1000 1,507 (12%) 167 (11%) 2.41 (1.99, 2.91) 1.74 (1.40, 2.15)
IDU: injection drug use; IQR: inter-quartile range; CI: conﬁdence interval
*Models adjusted for all variables in table, stratiﬁed by cohort.
doi:10.1371/journal.pone.0160460.t003
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and liver-related (18 [10%]). Adjusted HRs for specific causes of death stratified by age, sex,
CD4 count, viral suppression and AIDS are shown in Table 6. AIDS mortality was strongly
related to lower CD4 count and viral replication at ten years after starting ART. Cardiovascular
mortality was substantially higher in older patients (adjusted HR 8.95 [95% CI 3.63–22.1] com-
paring patients aged60 with<60 years at ten years after ART start). Transmission via IDU
and lower CD4 count at ten years after starting ART were strongly associated with mortality
from liver-disease. Non-AIDS mortality was associated with both older age, adjusted HR com-
pared with those aged<60 years 4.35 [95% CI 2.97–6.39], IDU status (3.40 [2.26–5.12]), lower
CD4 (2.42 [1.49–3.94]) and prior AIDS diagnosis (1.58 [1.27–1.95]). Deaths from suicide/acci-
dent were higher in those with a prior AIDS diagnosis. Other causes of death (combining all
causes with fewer than ten deaths) were strongly associated with older age (adjusted HR 5.71
[2.84,11.5]).
Discussion
Summary
Among HIV positive patients who started combination ART 1996–1999 without prior expo-
sure to antiretroviral drugs and survived for at least ten years, the majority were virally sup-
pressed and had CD4 counts500 cells/μL. Nonetheless lower CD4 count and lack of HIV-1
viral suppression at ten years after starting ART, and AIDS before or during the first decade of
ART, were strong predictors of death during the second decade of ART. Low CD4 count at
ART start was no longer associated with increased mortality beyond ten years after accounting
for CD4 count measured at ten years after starting ART. Compared with patients from other
risk groups, those who reported IDU as route of HIV transmission experienced higher mortal-
ity from ten years after ART start. The most frequently occurring causes of death were non-
AIDS-defining malignancy, followed by AIDS, cardiovascular, and liver-related causes. Older
age was strongly associated with cardiovascular mortality and with non-AIDS non-liver malig-
nancies, IDU with non-AIDS infection and liver-related mortality, and low CD4 count and
detectable viral replication at ten years after starting ART with AIDS mortality. The five-year
mortality risk was<5% in 60% of patients and was strongly age-related: fewer than 30% of
patients aged over 60 had five-year mortality risk less than 10%
Table 4. Unadjusted and adjusted hazard ratios (HR) according to CD4 count at start of ART and at 10 years after start of ART.
Cells/μL N (%) Unadjusted HR (95% CI) Adjusted HR (95% CI)*
CD4 count at start of ART (cells/μL) 350 4,296 (33%) 1 1
200–349 3,372 (26%) 1.09 (0.88, 1.35) 0.96 (0.77, 1.19)
100–199 2,120 (16%) 1.38 (1.09, 1.73) 0.94 (0.74, 1.20)
50–99 1,229 (9%) 1.60 (1.24, 2.08) 0.88 (0.67, 1.16)
0–49 1,994 (15%) 1.19 (0.94, 1.52) 0.69 (0.52, 0.90)
CD4 10 years after start of ART (cells/μL) 750 3,396 (26%) 1 1
500–749 4,093 (31%) 1.11 (0.85, 1.46) 1.04 (0.80, 1.37)
350–499 2,644 (20%) 1.72 (1.32, 2.25) 1.47 (1.12, 1.93)
200–349 1,850 (14%) 2.37 (1.81, 3.10) 1.92 (1.45, 2.54)
100–199 628 (5%) 4.28 (3.16, 5.78) 3.33 (2.42, 4.60)
0–99 400 (3%) 9.25 (6.90, 12.40) 6.85 (4.89, 9.60)
CI: Conﬁdence interval
*Adjusted for sex, regimen, age (16–39, 40–49, 50–59, 60–69,70 years), mode of transmission (IDU or not), HIV-1 RNA levels 10 years after start of ART
(0–50, 51–1000, >1000 copies/ml), AIDS status and mutually adjusted for both CD4 measurements and stratiﬁed by cohort.
doi:10.1371/journal.pone.0160460.t004
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Table 5. 5-year percentage risk of death (95% CI) from 10 years after start of ART, according to age, IDU risk group, AIDS status, CD4 count and
viral suppression (HIV RNA <50 copies/mL)*.
CD4 count 10 years after start of ART (cells/μL)
0–99 100–199 200–349 350–499 500–749 >750
Non-IDU, No AIDS, Virologically suppressed
Age 16–39 6.9 (4.9–9.8) 3.9 (2.7–5.5) 2.2 (1.6–3) 1.7 (1.2–2.3) 1.2 (0.9–1.6) 1.2 (0.8–1.6)
Age 40–49 10.9 (8.2–14.3) 6.1 (4.6–8.1) 3.5 (2.7–4.4) 2.7 (2.1–3.4) 1.9 (1.5–2.4) 1.9 (1.5–2.4)
Age 50–59 18.8 (14.3–24.4) 10.8 (8.2–14.2) 6.1 (4.8–7.8) 4.8 (3.8–6) 3.4 (2.7–4.3) 3.3 (2.6–4.3)
Age 60+ 36.4 (28.2–46.2) 22.1 (16.9–28.5) 12.9 (10.3–16.2) 10.1 (8.1–12.7) 7.2 (5.7–9.1) 7.1 (5.5–9.1)
Non-IDU, No AIDS, Not virologically suppressed
Age 16–39 11.3 (8.2–15.4) 6.4 (4.6–8.8) 3.6 (2.6–4.9) 2.8 (2–3.8) 2 (1.4–2.7) 1.9 (1.4–2.7)
Age 40–49 17.5 (13.7–22.1) 10 (7.7–13.1) 5.7 (4.5–7.2) 4.4 (3.5–5.6) 3.1 (2.4–4) 3.1 (2.4–4)
Age 50–59 29.3 (23.3–36.4) 17.4 (13.4–22.3) 10 (7.9–12.6) 7.8 (6.1–9.9) 5.6 (4.4–7.1) 5.5 (4.2–7.2)
Age 60+ 53 (43.1–63.6) 34 (26.6–42.8) 20.6 (16.4–25.7) 16.3 (12.8–20.6) 11.8 (9.1–15.1) 11.6 (8.8–15.2)
Non-IDU, AIDS, Virologically suppressed
Age 16–39 11.3 (8.1–15.8) 6.4 (4.6–9) 3.6 (2.6–4.9) 2.8 (2–3.8) 2 (1.4–2.7) 1.9 (1.4–2.7)
Age 40–49 17.6 (13.7–22.4) 10.1 (7.7–13.1) 5.7 (4.5–7.2) 4.4 (3.5–5.6) 3.2 (2.5–4) 3.1 (2.4–4)
Age 50–59 29.4 (23.3–36.8) 17.5 (13.6–22.3) 10.1 (8.1–12.6) 7.9 (6.3–9.8) 5.6 (4.5–7) 5.5 (4.3–7.1)
Age 60+ 53.2 (43.4–63.8) 34.2 (27.1–42.6) 20.7 (16.8–25.5) 16.4 (13.2–20.2) 11.8 (9.5–14.8) 11.7 (9.1–14.9)
Non-IDU, AIDS, Not virologically suppressed
Age 16–39 18.2 (13.4–24.3) 10.5 (7.6–14.4) 5.9 (4.3–8.1) 4.6 (3.3–6.3) 3.3 (2.4–4.5) 3.2 (2.3–4.6)
Age 40–49 27.6 (22.3–33.7) 16.3 (12.7–20.7) 9.4 (7.4–11.8) 7.3 (5.7–9.3) 5.2 (4–6.7) 5.1 (3.9–6.8)
Age 50–59 44.1 (36.7–52.2) 27.4 (21.9–33.9) 16.3 (13.1–20.1) 12.8 (10.2–16) 9.2 (7.2–11.7) 9 (6.9–11.8)
Age 60+ 71.8 (62.1–80.9) 50.2 (41–60.2) 32.1 (26.1–39.1) 25.8 (20.7–31.9) 19 (14.9–24) 18.7 (14.2–24.3)
IDU, No AIDS, Virologically suppressed
Age 16–39 13.5 (9.5–19.2) 7.7 (5.4–11) 4.3 (3.1–6.1) 3.4 (2.4–4.7) 2.4 (1.7–3.4) 2.3 (1.6–3.3)
Age 40–49 20.9 (15.8–27.2) 12.1 (9–16.1) 6.9 (5.3–8.9) 5.4 (4.1–7) 3.8 (2.9–5) 3.7 (2.8–5)
Age 50–59 34.4 (26–44.6) 20.7 (15.4–27.6) 12.1 (9.1–15.9) 9.5 (7.1–12.5) 6.8 (5–9) 6.6 (4.9–9)
Age 60+ 60.1 (47.3–73.3) 39.7 (30–51.3) 24.5 (18.5–31.9) 19.5 (14.6–25.7) 14.1 (10.5–18.9) 13.9 (10.2–19)
IDU, No AIDS, Not virologically suppressed
Age 16–39 21.5 (15.6–29.3) 12.5 (8.9–17.5) 7.1 (5.1–9.9) 5.6 (3.9–7.8) 3.9 (2.8–5.6) 3.9 (2.7–5.6)
Age 40–49 32.3 (25.5–40.4) 19.3 (14.7–25.2) 11.2 (8.6–14.6) 8.8 (6.6–11.5) 6.3 (4.7–8.3) 6.2 (4.5–8.4)
Age 50–59 50.5 (40.2–61.8) 32.1 (24.4–41.5) 19.3 (14.7–25.2) 15.3 (11.4–20.3) 11 (8.1–14.9) 10.8 (7.8–14.9)
Age 60+ 78.4 (66.2–88.6) 57 (44.7–70) 37.4 (28.7–47.8) 30.3 (22.8–39.6) 22.5 (16.5–30.2) 22.1 (15.9–30.3)
IDU, AIDS, Virologically suppressed
Age 16–39 21.7 (15.4–29.9) 12.6 (8.8–17.7) 7.2 (5.1–10.1) 5.6 (3.9–7.9) 4 (2.8–5.6) 3.9 (2.7–5.6)
Age 40–49 32.5 (25.4–40.9) 19.4 (14.8–25.3) 11.3 (8.7–14.6) 8.8 (6.8–11.5) 6.3 (4.8–8.3) 6.2 (4.6–8.3)
Age 50–59 50.7 (40.3–62.2) 32.3 (24.7–41.5) 19.4 (14.9–25.2) 15.3 (11.6–20.1) 11.1 (8.3–14.7) 10.9 (8–14.8)
Age 60+ 78.6 (66.5–88.7) 57.3 (45.4–69.7) 37.6 (29.2–47.4) 30.5 (23.3–39.2) 22.6 (16.9–29.8) 22.3 (16.3–29.9)
IDU, AIDS, Not virologically suppressed
Age 16–39 33.4 (24.9–44) 20.1 (14.4–27.6) 11.7 (8.4–16.2) 9.1 (6.4–12.9) 6.5 (4.5–9.3) 6.4 (4.4–9.4)
Age 40–49 48 (39.4–57.5) 30.3 (23.5–38.4) 18.1 (14–23.3) 14.3 (10.8–18.7) 10.3 (7.7–13.7) 10.1 (7.4–13.8)
Age 50–59 69.3 (58.5–79.5) 47.8 (37.8–58.9) 30.3 (23.4–38.5) 24.3 (18.4–31.6) 17.8 (13.2–23.7) 17.5 (12.7–23.9)
Age 60+ 92.4 (84.2–97.2) 75.8 (63.4–86.4) 54.4 (43.4–66.3) 45.4 (35.2–57.1) 34.7 (26–45.4) 34.3 (25.1–45.7)
*estimated fromWeibull model
doi:10.1371/journal.pone.0160460.t005
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Strengths and limitations
Strengths of this study include its large sample size, which meant we could investigate at risk
subgroups such as the IDU risk transmission group and older patients, and the inclusion of
patients from geographically diverse clinical cohorts in Europe and North America. As with
any observational study our results may have been affected by unmeasured confounders. We
could only include a limited number of prognostic factors in our study. The VACS Index
which includes hemoglobin, composite markers of liver and renal injury [FIB-4 and estimated
glomerular filtration rate (eGFR)] and hepatitis C status is a better predictor of mortality than
age, CD4 count and viral load alone, but many of the cohorts in ART-CC did not collect these
data [22]. Our results may have been affected by exclusion of patients without CD4 count and
Fig 1. Frequency distribution of patients grouped by five-year mortality risk, overall and by age-group.
doi:10.1371/journal.pone.0160460.g001
Table 6. Adjusted hazard ratios (HR) for specific causes of death, adjusted for all variables in the table and stratified by cohort, deaths = 218.
Adjusted HR (95% CI)
Cause of death N (%) Age60 vs.
<60 years
Female vs.
Male
IDU vs.
non-IDU
CD4 <200 vs.
200 cells/μL
HIV-1 RNA >50 vs.
50 copies/mL
Prior AIDS diagnosis 10 years
after ART start vs. no AIDS
AIDS 35
(16%)
1.08 (0.33,
3.58)
0.38 (0.13,
1.09)
1.24 (0.52,
2.96)
5.32 (2.49, 11.4) 4.90 (2.30, 10.4) 1.75 (1.16, 2.65)
Non-AIDS 145
(67%)
4.35 (2.97,
6.39)
0.70 (0.45,
1.06)
3.40 (2.26,
5.12)
2.42 (1.49, 3.94) 0.95 (0.62, 1.45) 1.58 (1.27, 1.95)
Cardiovascular disease 22
(10%)
8.95 (3.63,
22.1)
0.54 (0.16,
1.84)
2.20 (0.59,
8.23)
2.70 (0.71, 10.3) 1.30 (0.44, 3.80) 1.49 (0.84, 2.63)
Liver related 18 (8%) 1.65 (0.36,
7.50)
NA 3.84 (1.31,
11.2)
3.37 (1.11, 10.2) 2.37 (0.87, 6.40) 1.85 (1.02, 3.36)
Non-AIDS, non-liver
malignancies
45
(21%)
3.39 (1.71,
6.70)
0.81 (0.39,
1.68)
1.79 (0.77,
4.20)
1.62 (0.55, 4.80) 0.58 (0.24, 1.42) 0.88, 1.97)
Suicide/accident 13 (6%) 2.55 (0.65,
10.0)
1.28 (0.39,
4.24)
2.45 (0.62,
9.69)
2.19 (0.42,
11.34)
0.65 (0.13, 3.17) 2.45 (1.25, 4.80)
Other* 47
(22%)
5.71 (2.84,
11.5)
0.85 (0.42,
1.73)
6.21 (3.14,
12.3)
2.57 (1.11, 5.95) 0.93 (0.44, 1.95) 1.52 (1.04, 2.21)
Unknown 38
(17%)
4.72 (2.28,
9.77)
0.50 (0.19,
1.27)
3.33 (1.48,
7.53)
3.38 (1.31, 8.74) 0.61 (0.24, 1.55) 1.15 (0.73, 1.83)
IDU: injection drug use, CI: conﬁdence interval
* Causes with fewer than 10 deaths: these were non-AIDS Infection (8); heart or vascular (6); respiratory disease (5); chronic obstructive pulmonary disease
(4); renal failure (4); substance abuse (4); digestive system (4); central nervous system (3); lung embolus (1); other causes not included in CoDe
classiﬁcation system (15)
doi:10.1371/journal.pone.0160460.t006
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viral load measured during the 10th year of ART: such patients may attend care irregularly or
may have been receiving care temporarily in a clinic not contributing data to ART-CC. Our
results may only apply to patients who have survived 10 years on ART and continue to receive
regular care. Outcomes are unknown in patients who were LTFU but CD4 counts and the pro-
portion of patients virally suppressed were similar among those LTFU during the second
decade of ART and those remaining alive and in care. Most cohorts link to death registries and
so mortality rates among patients followed up in these cohorts should be reliably estimated
[23], but deaths may have been under-ascertained in cohorts without links to death registries.
Causes of death were classified according to a common protocol, but not all cohorts contrib-
uted data. However, the included deaths are likely representative of all deaths and we preferred
not to increase the proportion of unknown or unclassifiable deaths by including cohorts with
less complete data.
Context of research
Even in this cohort of patients who have survived at least ten years on ART, traditional markers
of HIV progression such as CD4 count, viral load, and AIDS events remain important risk fac-
tors warranting clinical attention. CD4 measurements at start of ART were unimportant com-
pared to those at ten years which is consistent with previous findings that recent or current
values of biomarkers best predict survival[13, 24] and that the prognostic importance of values
measured at start of ART diminish with time[15, 25]. Indeed, we found that for patients with
the same CD4 count at ten years after ART start, subsequent mortality was lower in patients
whose CD4 count had risen more over the first decade of ART, which may represent a selection
effect (“survival of the fittest”) as those who started ART with very low CD4 count were less
likely to have survived 10 years and be included in this analysis. In this unselected treatment
experienced population mortality rates remained substantially higher than in the general popu-
lation. By contrast, standardised mortality rates in highly selected groups on long term ART
who reached and maintained a CD4 count above 500 cells/ml have been found to approach
that of the general population[26–28]. However, a recent study from Denmark found that even
among well-treated HIV-infected individuals50 years without comorbidity or AIDS-defining
events the estimated median survival time remains lower than in the general population [29].
Older age was strongly associated with mortality, in particular that due to non-AIDS related
morbidity. This suggests that provision of both preventive and therapeutic health care in older
HIV-infected patients treated for many years will become increasingly important as the num-
ber of patients aged60 years old increases. The most common cause of death was non-AIDS
cancer, implying a need for preventive and screening measures adapted for use with HIV-posi-
tive patients who have survived long-term treatment with ART to be incorporated into their
routine health care[30].
Only a fifth of classifiable causes of death were due to AIDS, consistent with previous studies
that found low proportions of AIDS-related deaths in those treated for many years[26, 31, 32].
Although a substantial proportion of deaths soon after start of ART are AIDS-related,[5, 6, 8,
18, 24, 33–35] this proportion decreases with duration of ART. Correspondingly, the propor-
tion (though not the rate), of non-AIDS related deaths increases with time on ART[26, 31, 32].
Consistent with our study, the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D)
study found that most frequent causes of death in the 2009–11 follow-up period were due to
non-AIDS cancers, AIDS, cardiovascular disease, and liver disease[8].
It is only possible to study the long-term effects of antiretroviral therapy in patients who
started ART many years ago. Patients in our study will have been treated with the less potent
and more toxic drugs (compared with those currently available) available during 1996–99.
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Their management will have evolved as treatment guidelines changed and as new ART drugs
and drug combinations were approved[2–4, 36]. Therefore long-term mortality of patients
starting ART today can be expected to be lower than those found in our study. There is hetero-
geneity in mortality rates across cohorts[23] so that our estimates represent an average over
included cohorts.
Implications for health care
Given that a quarter of patients had detectable viral load at ten years after starting ART, careful
monitoring of patients treated for many years remains essential. The high burden of cancer
found in this and other HIV-infected populations[37] indicates the need to optimise and
improve adherence to screening guidelines[38, 39]. Higher mortality among patients diagnosed
with AIDS before ART start or within the first decade of treatment may arise from chronic or
late-onset sequelae of AIDS-defining illnesses, including relapse, secondary malignancy, heart
disease after anti-cancer chemotherapy[40] or chronic lung injury following infection with
Mycobacterium tuberculosis[41] or Pneumocystis jirovecii[42].
Patients reporting HIV transmission via IDU remained at considerably higher risk of mor-
tality, particularly death from liver-disease, beyond ten years after starting ART. This higher
mortality could arise from continued drug-use, co-infection with hepatitis C virus, higher rates
of smoking and alcohol abuse, or poorer adherence to treatment[43, 44]. Several participating
cohorts only assess IDU at enrolment, therefore we could not differentiate whether transmis-
sion risk of IDU remained a risk factor because of persisting drug use or because of direct
sequelae or adverse socioeconomic factors associated with historic drug use. It is likely that the
association of ongoing drug use with deaths from non-AIDS infection and substance use is
much greater than that estimated for the transmission risk group designated IDU in this study.
Current, but not former, drug use has been found to be associated with lack of adherence to
ART which in turn correlates with virological outcomes[45]. It is therefore important to
address continuing misuse of drugs and alcohol which may require opium substitution therapy
or counselling. IDU should be screened for hepatitis C and offered treatment if warranted.
Smokers should be offered nicotine substitution therapy and smoking cessation programs.
Reducing mortality in IDU may also require interventions to address depression and social
deprivation.
Conclusion
This study of patients who have survived ten years after starting ART found that CD4 count
and viral load remain important for prognosis. However, deaths were mostly non-AIDS-
related, and care for these patients should focus on improving management of non-HIV mor-
bidity, in particular risk factors and screening for non-AIDS cancer. Whilst the majority of
patients have low 5-year mortality risk, older patients have much higher risk. Patients with pre-
sumed transmission via IDU also have worse prognosis and likely require intensive manage-
ment with a variety of interventions that aim to reduce their excess mortality. Our estimates of
prognosis beyond ten years of ART could inform mathematical models[46] used to predict out-
comes and allow comparisons to be made against the observed data to test the validity of such
models. Our findings could also inform estimates of the future cost of treatment of people liv-
ing with HIV.
Appendix 1
Cohorts included in this paper were the French Hospital Database on HIV (FHDH); the Italian
Cohort of Antiretroviral-naïve patients (ICONA); the Swiss HIV Cohort Study (SHCS); the
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AIDS Therapy Evaluation project, Netherlands (ATHENA); The Multicenter Study Group on
EuroSIDA; the Aquitaine Cohort; the Royal Free Hospital Cohort, UK; the South Alberta
Clinic Cohort; Cohorte de la Red de Investigación en Sida (CoRIS), Spain; The Danish HIV
Cohort Study, Denmark; HAART Observational Medical Evaluation and Research (HOMER),
Canada; HIV Atlanta Veterans Affairs Cohort Study (HAVACS), USA; Osterreichische HIV-
Kohortenstudie (OEHIVKOS), Austria; Proyecto para la Informatizacion del Seguimiento
Clinico-epidemiologico de la Infeccion por HIV y SIDA (PISCIS), Spain; VACH, Spain; Veter-
ans Aging Cohort Study (VACS), USA; Vanderbilt, USA; University of Washington HIV
Cohort, USA; and the Koln/Bonn Cohort.
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